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Abstract
Objective—To determine whether maraviroc (MVC) has unique neurocognitive benefits in the 
context of initial antiretroviral therapy (ART).
Design—Randomized, double-blind, placebo-controlled, 48-week trial
Setting—Participants were enrolled in US domestic ACTG clinical trial sites.
Participants—262 ART naïve, CCR5 tropic HIV, and HIV RNA < 1000 cps/ml participants 
were randomized, 230 participants completed the study.
Intervention—Participants received MVC 150mg or tenofovir disoproxil fumarate (TDF) 300mg 
on a background of ritonavir-boosted darunavir and emtricitabine.
Main outcome measure(s)—The neuropsychological (NP) battery of 15 tests done at baseline, 
week 24 and week 48 assessed 7 domains, and were standardized into z scores then converted into 
deficit scores (DS) and a global deficit score (GDS). The 48-week changes from baseline in the 
NP scores and the GDS were compared by Wilcoxon or Kruskal-Wallis test between arms, and 
among baseline impairment groups (classified as normal, mild (2 DS ≥1) and moderate (2 DS 
≥2)). It was hypothesized that the MVC arm would have improved NP performance over TDF.
Results—In this double blind randomized placebo controlled trial, there were no differences in 
NP between MVC and TDF. Those with moderate NP impairment at baseline experienced greater 
ART-mediated NP improvement than those with mild or no NP impairment.
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Conclusions—Improvement in neurocognitive functioning was greater with more baseline 
impairment but was comparable with MVC or TDF.
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Introduction
The central nervous system (CNS) is a privileged compartment protected by the blood-brain 
barrier, which reduces influx of potentially toxic and therapeutic substances including 
antiretroviral drugs. Despite this protective barrier, HIV enters the CNS within days of 
infection, trafficking into the CNS through infected T-cells and monocytes [1]. In a minority 
of individuals, HIV establishes an autonomous, infection in the CNS [2]. Genetically 
distinct, or compartmentalized, HIV in the CNS has been correlated with HIV Associated 
Neurocognitive Disorders (HAND) [3]. In the current era of combination antiretroviral 
treatment (cART), subtle or mild neurocognitive deficits are prevalent in almost 40% of 
those who have effective treatment and despite having successfully suppressed systemic 
viral replication [4].
Although the mechanism of neuronal injury underlying HAND remains to be completely 
elucidated, HIV replication within the CNS is thought to drive an inflammatory process by 
inducing cytokine production that impairs neuronal functioning and eventually leads to 
neuronal cell death [1, 5]. Up to 10% of individuals receiving ART experience ongoing HIV 
replication and its consequences in the CNS despite having undetectable HIV RNA in 
plasma, a phenomenon known as CNS escape [6-8]. HIV may also establish a quiescent, 
non-replicating infection within the CNS, possibly contributing to inflammation, neuronal 
dysfunction and ultimately HAND [9]. Controlling HIV replication and viral load in the 
CNS and associated inflammatory processes could lead to improved neurocognitive 
outcomes and reduce the current prevalence of mild HAND.
The main co-receptor for HIV entry into target cells is the chemokine coreceptor 5 (CCR5). 
The antiretroviral maraviroc (MVC) is an effective inhibitor of CCR5. MVC is also thought 
to have anti-inflammatory effects, since CCR5 is a primary ligand of macrophage 
inflammatory protein -1 alpha (MIP-1α) which is pro-inflammatory [10]. In a rat model, 
CCR5 inhibition downregulated proinflammatory matrix metalloproteinase-9 [11], and in a 
macaque model MVC reduced replicating and latent Simian Immunodeficiency Virus (SIV) 
as well as monocyte and macrophage activation in the brain [12]. Small clinical studies in 
HIV-1 infected individuals have also suggested that intensifying ART with MVC may 
improve neuronal integrity [13] or neurocognitive performance [14]. On the other hand, 
CCR5 deficiency has been associated with worse outcomes during CNS viral infections [15, 
16], and an animal study reported increased microglial activation with MVC, suggesting the 
possibility of exacerbating neuronal pathology with chronic MVC use [17]. To ascertain the 
effects of MVC on HAND, we investigated changes in neuropsychological performance in 
AIDS Clinical Trials Group (ACTG) study A5303 [ClinicalTrials.gov. Identifier: NCT 
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01400412], a randomized, double blind, clinical trial of MVC-versus tenofovir disoproxil 
fumarate (TDF)-containing ART in treatment naïve HIV-1-infected participants. Our 
hypothesis was that MVC would be associated with greater improvement in 
neuropsychological performance compared to TDF since MVC has potential anti-
inflammatory effects in addition to antiviral effects.
Methods
Study design
As detailed in the primary publication [18], A5303 was a phase 2, prospective, double-blind, 
placebo-controlled, randomized multicenter, 48-week clinical trial conducted between 
January 2012 and June 2014 at 33 ACTG and 4 Adolescent Trials Network research sites in 
the US. Individuals whom the site investigator felt could not complete the neurocognitive 
protocol due to HIV or other illness, and those with HIV associated neurological disease as 
documented by their clinical provider were excluded. The study enrolled 262 ART-naïve 
HIV-1-infected participants (18 years or older) with plasma viral load (VL) greater than 
1000 copies/mL and R5 tropism on the Trofile® phenotypic assay [Monogram Biosciences, 
South San Francisco, California]. The Institutional Review Board of each study site 
approved the protocol. Each subject provided a written informed consent (Clinicaltrials.gov 
identifier NCT01400412).
Study Procedures
Participants received MVC 150 mg or TDF 300 mg (1:1 ratio), each combined with 
darunavir (DRV) 800 mg, ritonavir (RTV) 100 mg and emtricitabine (FTC) 200 mg once 
daily. Randomization was stratified by screening VL < or ≥ 100,000 copies/mL and age <30 
or ≥30 years.
Neurocognitive Assessment
Neuropsychological performance was assessed at study entry, week 24, and week 48. The 
neuropsychological battery consisted of 15 tests assessing the following 7 domains 
(measures): Language/Premorbid skills (WRAT-4 Reading [19]), Verbal Learning (Hopkins 
Verbal Learning Test Revised [20] learning trials), Attention/Working Memory (WAIS-III 
Symbol Search [21], Stroop Word [23,24]), Speed of Information Processing (Digit Symbol 
[21], Trailmaking A [22], Stroop color naming [24]), Executive Function (Trailmaking B 
[22], Stroop Interference [23,24], Letter Fluency, Semantic Verbal Fluency [25,26]), Fine 
Motor Skills (Grooved Pegboard bilateral [27], [28]), and Verbal Memory (Delayed Recall – 
HVLT-R [20], Recognition – HVLT-R [20]). Participants also completed an assessment of 
Activities of Daily Living (ADL) to assess functional ability [30].
The tests were averaged into two summary scores: total z score and global deficit score 
(GDS)[31]. Total z score was computed through the average of the 15 individual test z 
scores. Individual test z scores were computed by subtracting the test raw score from the 
demographically corrected normative score adjusted for age, education, gender, and race 
where appropriate, then dividing by the normative standard deviation [32]. Resulting z 
scores vary around zero which reflects average performance, positive scores denote better 
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than average performance, and negative scores reflect impaired performance. GDS was 
computed through the average of the individual test deficit scores (DS). Increasing positive 
scores from zero reflect increasing deficits or impairment; 1 reflects mild impairment while 
5 reflects severe impairment. Deficit scores set to 0 any normal or above normal 
performances, and thus avoid issues of summing positive and negative performances [29]. 
Deficit scores were computed as follows: 0 (z >-1); 1 (-1.5 ≤ z ≤-1); 2 (-2.0 ≤ z <-1.5); 3 
(-2.5 ≤ z <-2.0); 4 (-3.0 ≤ z <-2.5); and 5 (z ≤ -3.0); missing if z-score is missing. For 
domains, z score and deficit scores were computed. The total ADL score is the sum of 16 
ADL scores (excluding score 8, not applicable). Question 5 of the ADL questionnaire has 
scores 1, 2, and 3 so that it was changed to 0, 1, and 2.
To ensure that the neuropsychological tests were done consistently across the study sites, all 
staff assigned to administer the tests received appropriate training and certification under the 
supervision of a neuropsychologist (KR). Staff training was supported by several 
mechanisms: in-person training at the annual ACTG meetings, video training films, and 
PowerPoint presentations. After the initial training and completion of a web-based 
certification test, subsequent review of the training materials and re-certification of the 
research staff occurred at least annually.
Neurocognitive Impairment
Mild neurocognitive impairment was defined as having at least 2 neurocognitive domains 
with the mean domain DS of 1 or more. Moderate neurocognitive impairment was defined as 
having at least 2 neurocognitive domains with the mean domain DS of 2 or more. We also 
defined impairment according to conventional HAND categorization [31]: Normal (DS < 1 
for all domains, ADL = 0); Asymptomatic Neurocognitive Impairment (ANI, DS ≥ 1 for at 
least 2 domains, ADL = 0); Mild Neurocognitive Disorder (MND, DS ≥ 1 for at least 2 
domains and ADL ≥ 1, or DS ≥ 2 for 2 domains and ADL 0-3); HAD (DS ≥ 2 for 2 
domains, ADL ≥ 4).
Other Study Procedures
Routine study visits for safety, virologic, and immunologic assessments occurred at week 4 
(±7 days), and weeks 16, 24, 36, and 48, all ±14 days. Adherence to study medications was 
assessed by self-report at all study visits post-entry except week 36.
Statistical analyses
The 24 and 48-week changes in the individual test z scores, the total z score, and the GDS 
were compared by Wilcoxon rank sum tests between study treatment arms, and by Kruskal-
Wallis test between the baseline impairment groups. The changes from baseline, week 24 
and week 48 total z scores were assessed by Wilcoxon signed rank tests. All analyses were 
as-treated and included only participants who remained on their randomized MVC or TDF 
component by week 48 without an interruption in treatment of more than 10 weeks with 
available data for both baseline and week 48. If participants were unable to perform any 
individual test because of a reason unrelated to HIV associated neurological disease their 
individual test z scores were treated as missing. All statistical tests were two-sided and 
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interpreted at the 5% nominal level of significance without adjustment for multiple 
comparisons. Analyses were conducted using SAS statistical software 9.4.
Results
Baseline Characteristics
Two hundred and thirty participants were randomized to the MVC (N= 119) versus TDF arm 
(N=111) (Table 1). The arms were comparable by sex (total 91% male), and age (median 
age 33 years; IQR, 26-42). Eighty-two percent were English speakers, 9% were Spanish 
speakers, and 70% had at least some college education. Baseline characteristics were similar 
between the study arms, except for a chance racial imbalance with more non-Hispanic 
blacks in the MVC arm (total 44% Non-Hispanic White, and 31% Non-Hispanic Black, p<.
05). Both arms were also comparable by HIV viral load (total median plasma HIV RNA 4.5 
log10 copies/mL; IQR 4.0, 5.0) and current immune functioning (total CD4 count 389 
cells/mm3; IQR 293, 508).
At baseline, individual z scores, total z scores, GDS scores and well as domain z scores (fine 
motor, speed of processing, executive functioning, verbal learning, verbal memory, and 
attention score) were similar between the MVC and TDF arms. For example, there were no 
significant differences in GDS between the arms at baseline (median MVC 0.33; IQR 0.07, 
0.73 vs. median TDF 0.33; IQR 0.13, 0.64). At baseline, 55% of participants were normal 
and 45% had a HAND diagnosis. ANI was found in 12.2%, MND in 30.6% and 2.2% HAD. 
None of the participants were unable to perform a test because of a reason related to HIV 
associated neurological disease.
Neurocognitive Change by Treatment Arm
The primary analysis was to compare changes in neurocognitive performance (total z score 
and GDS) by arm from baseline to weeks 24 and 48. Most neurocognitive test performances 
improved through week 48 and were significantly better than the baseline performance. The 
median (IQR) GDS was 0.3 (0.1, 0.7) at baseline and 0.2 (0.0, 0.5) at week 48. The median 
(IQR) 48-week change in the GDS was -0.08 (-0.27, 0) (p-value < 0.001). There were no 
significant differences in neurocognitive performance for z score or GDS between the MVC 
and TDF arms at 24 weeks or 48 weeks (see Appendix and Figure 1).
Neurocognitive Change by Baseline Neurocognitive Status
Those with GDS normal baseline functioning had very little changes, while those with GDS 
mild and moderate impairment improved from baseline to 48 weeks (p-value < 0.001; Figure 
2). The median (IQR) 48 week change in GDS was 0.0 (-0.1, 0.1) for unimpaired (n=126), 
-0.2 (-0.3, -0.1) for mildly impaired (n=69), and -0.4 (-0.7, -0.2) for moderately impaired 
(n=35). For HAND diagnoses, among participants with ANI, MND, or HAD at baseline, 
there was greater improvement in those with more severe HAND at baseline (p < 0.001). 
The median (IQR) 48 week change in GDS was 0.0 (-0.1, 0.1) for unimpaired (n=126), -0.2 
(-0.3, 0.1) for ANI (n=28), -0.3 (-0.6, -0.1) for MND (n=70), and -0.7 (-0.7, -0.3) for HAD 
(n=5). Fifteen ANI participants (53.6%) at baseline, 33 MND participants (48.5%), and 3 
HAD participants (60.0%) became unimpaired at week 48.
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ART initiation has been shown to improve overall neurocognitive performance [34], [35]. 
We found that ART initiation with either MVC-containing or TDF-containing regimens 
significantly improved neurocognitive functioning. The neurocognitive improvement is a 
combination of antiretroviral effects due to viral suppression, as well as learning and 
practice effects [34] Those with worse baseline functioning had greater improvement. Since 
neurocognitively impaired individuals generally have poorer learning abilities and less 
practice effects, our findings suggest that improvements in this study were driven more by 
ART as opposed to learning/practice effects.
We found no apparent advantage for neurocognitive performance with MVC over TDF 
containing regimens. The primary results of A5303 also showed similar efficacy in 
suppressing plasma HIV-1 viremia with both the MVC-containing and TDF-containing 
antiretroviral regimens [18].
The neuropathogenesis of HAND is likely related to neuronal dysfunction and death due to 
neuroinflammation induced in response to HIV [37, 38]. Thus, anti-inflammatory adjunctive 
therapies may be effective for treating HAND. While several potential neuroprotective 
pathways for MVC have been proposed [12], our results suggest that at least in the context 
of ART initiation, MVC does not produce unique modulation of the inflammatory pathways 
underlying HAND beyond what is attributable to control of viral replication or that 
modulation of these pathways does not lead to a measureable change in neurocognitive 
function over a short period following ART initiation. MVC may have independent anti-
inflammatory effects that were not detected because their magnitude was modest relative to 
the effects produced by controlling viral replication. Of note, a small open label single arm 
study found neurocognitive improvement among impaired participants whose ART was 
intensified with MVC [14]. Another study [39] found that in those with diagnosed HAND 
on ART, intensification with MVC improved neurocognition over those with no change in 
ART. A study investigating switching to maraviroc in participants with HIV-associated 
neurocognitive impairment found a trend towards neurocognitive improvement [40]. These 
pilot studies suggest that MVC may confer neurocognitive benefits when used to intensify 
ART in contrast to our results in ART naïve participants. Notably, studies of the immune 
effects of MVC have also produced mixed results with a recent open label MVC 
intensification study reporting decreased immune activation [41], while a randomized MVC 
intensification study in those with incomplete CD4 restoration found contradictory immune 
activation effects [42] One possibility is that MVC has several effects, including some that 
are potentially beneficial to the CNS (such as good CNS penetration and reduction in 
trafficking of activated T cells and monocytes) counterbalanced by other effects that may not 
be beneficial Neurocognitive impairment remains a relatively prevalent problem in those 
who are treatment naïve and immunosuppressed, and to some extent in those who are virally 
suppressed on ART. We found substantial overall neurocognitive improvement on ART 
regardless of regimen, with 51 of the 104 (49%) impaired participants returning to normal 
functioning. However, neurocognitive impairment was persistent in some of our participants, 
23% of all participants, and 51% of those impaired at baseline, similar to the results of other 
studies such as CHARTER [43]. Based on the findings of this study, the largest US 
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randomized and double blind trial in HAND to date, inclusion of MVC in initial ART 
regimens is unlikely to provide unique neurocognitive benefits compared to other potent 
ART combinations in treatment naïve individuals. A large double blind randomized placebo 
controlled study (ACTG A5324) is ongoing to determine whether MVC has a beneficial 
effect when used to intensify ART in virologically suppressed HIV-1 patients with 
neurocognitive impairment.
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Appendix: 24- and 48-week changes in GDS, total z-score, and domain z-
scores by arm










n Median (IQR) n Median (IQR) n Median (IQR) n Median (IQR)
Global deficit score 116 -0.1 (-0.2, 0.1) 108 -0.1 (-0.3, 0.1) 0.732 116 -0.1 (-0.3, 0.0) 109 -0.1 (-0.3, 0.0) 0.356
Total z-score 116 0.2 (-0.1, 0.4) 108 0.3 (0.0, 0.4) 0.335 116 0.3 (0.0, 0.5) 109 0.3 (0.1, 0.5) 0.233
Domain z-scores
 Fine motor 115 0.2 (-0.3, 0.8) 108 0.4 (-0.2, 0.8) 0.436 115 0.4 (-0.2, 0.8) 109 0.5 (0.0, 0.8) 0.485
 Speed of processing 116 0.2 (-0.2, 0.6) 108 0.2 (-0.2, 0.6) 0.670 116 0.3 (-0.2, 0.7) 109 0.4 (-0.0, 0.8) 0.241
 Executive functioning 116 0.1 (-0.1, 0.5) 108 0.2 (-0.1, 0.5) 0.414 116 0.3 (-0.1, 0.6) 109 0.3 (0.0, 0.6) 0.476
 Verbal learning 115 0.3 (-0.4, 1.0) 106 0.3 (-0.3, 1.0) 0.618 115 0.4 (-0.2, 1.0) 107 0.4 (-0.2, 1.0 0.869
 Verbal memory 114 0.1 (-0.4, 0.7) 108 0.0 (-0.3, 0.6) 0.705 114 0.1 (-0.3, 0.7) 109 0.0 (-0.2, 0.6) 0.797
 Attention domain 116 0.1 (-0.3, 0.4) 108 0.2 (-0.2, 0.6) 0.303 116 0.1 (-0.2, 0.5) 109 0.3 (-0.1, 0.7) 0.077
References
1. Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, et al. Cerebrospinal fluid and 
neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals 
during primary HIV infection. J Infect Dis. 2013 Jun 1; 207(11):1703–12. [PubMed: 23460748] 
2. Joseph SB, Arrildt KT, Sturdevant CB, Swanstrom R. HIV-1 target cells in the CNS. J Neurovirol. 
2015; 21(3):276–89. [PubMed: 25236812] 
3. Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R. Increased human immunodeficiency virus 
type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol. 
2005; 79(16):10830–4. [PubMed: 16051875] 
Robertson et al. Page 7













4. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and 
incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21(14):1915–21. 
[PubMed: 17721099] 
5. Airoldi M, Bandera A, Trabattoni D, Tagliabue B, Arosio B, Soria A, et al. Neurocognitive 
impairment in HIV-infected naive patients with advanced disease: the role of virus and intrathecal 
immune activation. Clin Dev Immunol. 2012; 2012:467154. [PubMed: 22489249] 
6. Ferretti F, Gisslen M, Cinque P, Price RW. Cerebrospinal Fluid HIV Escape from Antiretroviral 
Therapy. Curr HIV/AIDS Rep. 2015; 12(2):280–8. [PubMed: 25860317] 
7. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance 
between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms 
who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010; 50(5):773–8. [PubMed: 
20100092] 
8. Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape 
associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well 
controlled plasma viral load. AIDS. 2012; 26(14):1765–74. [PubMed: 22614889] 
9. Bednar MM, Sturdevant CB, Tompkins LA, Arrildt KT, Dukhovlinova E, Kincer LP, et al. 
Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS. Curr HIV/AIDS Rep. 
2015 Jun; 12(2):262–71. [PubMed: 25914150] 
10. Menten P, Wuyts A, van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor 
Rev. 2002; 13:455–481. [PubMed: 12401480] 
11. Gramegna P, Latronico T, Branà MT, Di Bari G, Mengoni F, Belvisi V, et al. In vitro 
downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: 
therapeutic implication for HIV brain infection. PLoS One. 2011; 6(12)
12. Kelly KM, Beck SE, Metcalf Pate KA, Queen SE, Dorsey JL, Adams RJ, et al. Neuroprotective 
maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating 
and latent SIV in the brain. AIDS. 2013; 27(18):F21–8. [PubMed: 24051706] 
13. Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, et al. CNS effects of a CCR5 
inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob 
Chemother. 2012; 67(1):206–12. [PubMed: 21987241] 
14. Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, et al. Treatment 
intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes 
in cART-suppressed chronic HIV-infected subjects and is associated with improvements in 
neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). 
J Neurovirol. 2014; 20(6):571–82. [PubMed: 25227930] 
15. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, et al. A deletion in the 
chemokine receptor 5 (CCR5) gene is associated with tick-borne encephalitis. J Infect Dis. 2008; 
197:266–32. [PubMed: 18179389] 
16. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, et al. Genetic deficiency of 
chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a 
meta-analysis of 4 cohorts in the US epidemic. J Infect Dis. 2008; 197:262-. [PubMed: 18179388] 
17. Lisi L, Tramutola A, De Luca A, Navarra P, Dello Russo C. Modulatory effects of the CCR5 
antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. J Neurochem. 
2012 Jan; 120(1):106–14. [PubMed: 22017448] 
18. Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, et al. Less Bone Loss 
With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials 
Group A5303 Study. Clin Infect Dis. 2015; 61(7):1179–88. [PubMed: 26060295] 
19. Wilkinson, GS.; Robertson, GJ. Wide range achievement test-fourth edition: Professional manual. 
Lutz, FL: Psychological Assessment Resources; 2006. 
20. Brandt, J.; Benedict, RHB. The Hopkins Verbal Learning Test–Revised. Lutz, FL: Psychological 
Assessment Resources; 2001. 
21. Wechsler, D. WMS-III: Administration and Scoring Manual. San Antonio, TX: Psychological 
Corporation Harcourt Brace & Co; 1997. 
Robertson et al. Page 8













22. Reitan, RM.; Davison, LA. Clinical Neuropsychology: Current status and applications. New York: 
Winston/Wiley; 1974. Manual of Directions and Scoring. Washington, DC: War Department, 
Adjutant General's Office; 1944. Army Individual Test Battery. 
23. Stroop JR. Studies of interference in serial verbal reactions. J ExperPsychol. 1935; 18:643–662.
24. Comalli PE Jr, Wapner S, Werner H. Interference effects of Stroop color-word test in childhood, 
adulthood, and aging. J Genet Psychol. 1962 Mar.100:47–53. [PubMed: 13880724] 
25. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures 
of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999; 14(2):167–177. 
[PubMed: 14590600] 
26. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK. Norms for letter and 
category fluency: Demographic corrections for age, education, and ethnicity. Assessment. 1999; 
6:147–178. [PubMed: 10335019] 
27. Klove, H. Clinical neuropsychology. In: Forster, EM., editor. The Medical Clinics of North 
America. New York: Saunders; 1963. 
28. Ruff RM, Parker SB. Gender- and age-specific changes in motor speed and eye-hand coordination 
in adults: Normative values for the Finger Tapping and Grooved Pegboard tests. Perceptual and 
Motor Skills. 1993; 76(3c):1219–1230. [PubMed: 8337069] 
29. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. HNRC Group. 
Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV 
infection. J Clin Exp Neuropsychol. 2004 May; 26(3):307–19. [PubMed: 15512922] 
30. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities 
of daily living. Gerontologist. 1969 Autumn;9(3):179–86. [PubMed: 5349366] 
31. Blackstone K 1, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining 
neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol. 2012; 
26(6):894–908. Epub 2012 Jun 18]. DOI: 10.1080/13854046.2012.694479 [PubMed: 22708483] 
32. Heaton, RK.; Miller, SW.; Taylor, MJ.; Grant, I. Revised comprehensive norms for an expanded 
Halstead-Reitan battery: demographically adjusted neuropsychological norms for African 
American and Caucasion adults scoring program. Lutz, FL: American Psychological Assessment 
Resourcse, Inc.; 2004. 
33. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology 
for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30; 69(18):1789–99. [PubMed: 
17914061] 
34. Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, Evans S, Campbell TB, et al. AIDS Clinical 
Trials Group. Improved neuropsychological and neurological functioning across three 
antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study 
a5199, the International Neurological Study. Clin Infect Dis. 2012 Sep; 55(6):868–76. [PubMed: 
22661489] 
35. Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, et al. Highly active 
antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004 
May 1; 36(1):562–6. [PubMed: 15097298] 
36. Grund B, Wright EJ, Brew BJ, Price RW, Roediger MP, Bain MP, et al. INSIGHT SMART Study 
Group. Improved neurocognitive test performance in both arms of the SMART study: impact of 
practice effect. J Neurovirol. 2013 Aug; 19(4):383–92. [PubMed: 23943468] 
37. Zayyad Z 1, Spudich S. Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated 
neurocognitive disorder (HAND). Curr HIV/AIDS Rep. 2015 Mar; 12(1):16–24. [PubMed: 
25604237] 
38. Chen MF, Gill AJ, Kolson DL. Neuropathogenesis of HIV-associated neurocognitive disorders: 
roles for immune activation, HIV blipping and viral tropism. Curr Opin HIV AIDS. 2014 Nov; 
9(6):559–64. [PubMed: 25203638] 
39. Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. Maraviroc-intensified 
combined antiretroviral therapy improves cognition in virally suppressed HIV-associated 
neurocognitive disorder. AIDS. 2016 Feb 20; 30(4):591–600. [PubMed: 26825032] 
40. Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, et al. 
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated 
Robertson et al. Page 9













neurocognitive impairment during antiretroviral treatment switch. HIV Med. 2015 Jul; 16(6):388–
92. [PubMed: 25721471] 
41. Cillo A, Hilldorfer B, Lalama C, McKinnon J, Coombs R, Tenorio A, et al. Virologic and 
immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with 
suboptimal CD4+ T-cell recovery. AIDS. Oct 23; 2015 29(16):2121–2129. [PubMed: 26544577] 
42. Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, et al. The immunologic 
effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-
cell recovery: a randomized trial. Blood. 2013 Jun 6; 121(23):4635–46. [PubMed: 23589670] 
43. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. CHARTER Group. 
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: 
CHARTER Study. Neurology. 2010 Dec 7; 75(23):2087–96. [PubMed: 21135382] 
Robertson et al. Page 10













Figure 1. Median (IQR) 48-week change in GDS by arm
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Figure 2. Median (IQR) 48-week change in GDS by baseline impairment group
Robertson et al. Page 12

























Robertson et al. Page 13
Table 1
Baseline demographic characteristics by treatment arm
Characteristic MVC (n=119) TDF (n=111) All Participants (n=230)
Male – no. (%) 105 (88%) 104 (94%) 209 (91%)
Race – no. (%)
 White Non-Hispanic 51 (43%) 51 (46%) 102 (44%)
 Black Non-Hispanic 43 (36%) 29 (26%) 72 (31%)
Hispanic (Regardless of Race) – no. (%) 21 (18%) 29 (26%) 50 (22%)
 Asian, Pacific Islander 2 (2%) 1 (1%) 3 (1%)
 American Indian, Alaskan Native 0 (0%) 1 (1%) 1 (0%)
 More than one race 2 (2%) 0 (0%) 2 (1%)
Age – year
 Median (IQR) 33 (27, 43) 33 (26, 42) 33 (26, 42)
Primary Language – no. (%)
 English 97 (82%) 91 (82%) 188 (82%)
 Spanish 12 (10%) 9 (8%) 21 (9%)
 Unknown 8 (7%) 10 (9%) 18 (8%)
Educational Status – no. (%)
 < 12 years 9 (8%) 9 (9%) 18 (9%)
HAND diagnosis – no. (%)
 Normal 66 (55%) 60 (54%) 126 (55%)
 Asymptomatic Neurocognitive Impairment 13 (11%) 15 (14%) 28 (12%)
 Mild Neurocognitive Disorder 37 (31%) 33 (30%) 40 (17%)
 HIV Associated Dementia 3 (3%) 2 (2%) 35 (15%)
 Missing* 0 1 1 (1%)
*
HIV Associated Neurocognitive Disorder (HAND) diagnosis could not be computed due to missing ADL score.
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